Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative Intravitreal Triamcinolone Acetonide in Rhegmatogenous Retinal Detachment
NCT07774182Completed
- Start
- May 2025
- Primary completion
- Feb 2026
- Countries
- 1
01
Overview
Randomised trial of triamcinolone acetonide in rhegmatogenous retinal detachment (RRD) and Proliferative Vitreoretinopathy (PVR) (2 arms). Primary endpoint: Change in Aqueous Humor TGF-β2, TGF-β3, MMP-2, and MMP-9 Levels. Started May 2025; status: completed.
02
Drugs
triamcinolone acetonide
03
Conditions
rhegmatogenous retinal detachment (RRD)Proliferative Vitreoretinopathy (PVR)
Beyond the preview
Go deeper on NCT07774182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07774182.